Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C BURNETT

Showing results (691-700 of 921) with videos related to

Pageof 93
Sort By:
Circulation Research|December 14, 2002
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinasesToshihiro Tsuruda, Guido Boerrigter, Brenda K Huntley, et al.
Trends in Endocrinology and Metabolism: TEM|July 4, 2006
Membrane guanylyl cyclase receptors: an updateDavid L Garbers, Ted D Chrisman, Phi Wiegn, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|February 9, 2007
Impaired functional status and echocardiographic abnormalities signifying global dysfunction enhance the prognostic significance of previously unrecognized myocardial infarction detected by electrocardiographyKhawaja Afzal Ammar, Ravindrakumar Makwana, Steven J Jacobsen, et al.
Journal of Molecular and Cellular Cardiology|April 8, 2019
C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblastsYang Chen, Ye Zheng, Seethalakshmi R Iyer, et al.
Journal of Cardiac Failure|July 26, 2002
The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failureShang-Chiun Lee, Tracy L Stevens, Sharon M Sandberg, et al.
Circulation|February 6, 2002
Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failureAlessandro Cataliotti, Guido Boerrigter, Horng H Chen, et al.
Plos One|July 9, 2010
Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype AJorge E Zuniga, Jared T Hammill, Omri Drory, et al.
Heart (British Cardiac Society)|March 31, 2010
Progression of preclinical diastolic dysfunction to the development of symptomsDaniel D Correa de Sa, David O Hodge, Joshua P Slusser, et al.
Journal of Medicinal Chemistry|September 16, 2005
A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approachTam Luong Nguyen, Connor McGrath, Ann R Hermone, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|November 16, 2004
Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulinIan Z MacKenzie, Johann Bichler, Gerald C Mason, et al.
Pageof 93

Showing results (691-700 of 921) with videos related to

Sort By:
Pageof 93
Circulation Research|December 14, 2002
Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinasesToshihiro Tsuruda, Guido Boerrigter, Brenda K Huntley, et al.
Trends in Endocrinology and Metabolism: TEM|July 4, 2006
Membrane guanylyl cyclase receptors: an updateDavid L Garbers, Ted D Chrisman, Phi Wiegn, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|February 9, 2007
Impaired functional status and echocardiographic abnormalities signifying global dysfunction enhance the prognostic significance of previously unrecognized myocardial infarction detected by electrocardiographyKhawaja Afzal Ammar, Ravindrakumar Makwana, Steven J Jacobsen, et al.
Journal of Molecular and Cellular Cardiology|April 8, 2019
C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblastsYang Chen, Ye Zheng, Seethalakshmi R Iyer, et al.
Journal of Cardiac Failure|July 26, 2002
The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failureShang-Chiun Lee, Tracy L Stevens, Sharon M Sandberg, et al.
Circulation|February 6, 2002
Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failureAlessandro Cataliotti, Guido Boerrigter, Horng H Chen, et al.
Plos One|July 9, 2010
Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype AJorge E Zuniga, Jared T Hammill, Omri Drory, et al.
Heart (British Cardiac Society)|March 31, 2010
Progression of preclinical diastolic dysfunction to the development of symptomsDaniel D Correa de Sa, David O Hodge, Joshua P Slusser, et al.
Journal of Medicinal Chemistry|September 16, 2005
A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approachTam Luong Nguyen, Connor McGrath, Ann R Hermone, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|November 16, 2004
Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulinIan Z MacKenzie, Johann Bichler, Gerald C Mason, et al.
Pageof 93